Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial

ALEJANDRO ESCUDERO CONTRERASALEJANDRO ESCUDERO CONTRERASJUAN ANTONIO MORENO GUTIERREZ2026-01-292026-01-29201910.1002/art.409052-s2.0-85067626906https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/30539ImmunologyImmunology and AllergyRheumatologyReducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trialresearch article